1
|
Teodoro Nepomuceno G, Silva Neres Dos Santos R, Avance Pavese L, Parize G, Pallos D, Sorelli Carneiro-Ramos M, da Silva Martinho H. Periodontal disease in chronic kidney disease patients: salivomics by Fourier-transform infrared spectroscopy. JOURNAL OF THE OPTICAL SOCIETY OF AMERICA. A, OPTICS, IMAGE SCIENCE, AND VISION 2023; 40:C93-C100. [PMID: 37132977 DOI: 10.1364/josaa.482903] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/04/2023]
Abstract
It has been reported that 58% of individuals with chronic kidney disease (CKD) have moderate to advanced periodontitis due to alterations of pH and biochemical composition in the saliva. In fact, the composition of this important biofluid may be modulated by systemic disorders. Here we investigate the micro-reflectance Fourier-transform infrared spectroscopy (FTIR) spectra of saliva that CKD patients submitted to periodontal treatment, aiming to identify spectral biomarkers of kidney disease evolution and the effectiveness of periodontal treatment, proposing possible biomarkers of disease evolution. Saliva from 24 CKD patients-stage-5 men, 29 to 64 years old-was evaluated in (i) patients starting periodontal treatment; (ii) patients 30 days after periodontal treatment; and (iii) patients 90 days after periodontal treatment. Our findings indicated that there are statistically relevant changes among the groups after 30 and 90 days of periodontal treatment, when considering the overall spectra in the fingerprint region (800-1800cm-1). The key bands presenting good prediction power (area under the receiver operating characteristic curve >0.70) were related to poly (ADP-ribose) polymerase (PARP) conjugated to DNA at 883, 1031, and 1060cm-1 (carbohydrates at 1043 and 1049cm-1) and triglycerides (1461cm-1). Interestingly when analyzing the derivative spectra in the secondary structure region (1590-1700cm-1), we detected over-expression of the β-sheet class of secondary structures in 90 days of periodontal treatment, possibly related to over-expression of human B-defensins. Conformational changes in ribose sugar in this region corroborate the interpretation concerning PARP detection. To our knowledge, PARP was detected for the first time in saliva samples of stage-5 CKD patients by FTIR. All observed changes were correctly interpreted in terms of intensive apoptosis and dyslipidemia due to kidney disease progression. Biomarkers due to CKD predominate in saliva, and the relative improvement in the periodontal state did not cause remarkable changes in the spectra of saliva.
Collapse
|
2
|
El Amki M, Lerouet D, Garraud M, Teng F, Beray-Berthat V, Coqueran B, Barsacq B, Abbou C, Palmier B, Marchand-Leroux C, Margaill I. Improved Reperfusion and Vasculoprotection by the Poly(ADP-Ribose)Polymerase Inhibitor PJ34 After Stroke and Thrombolysis in Mice. Mol Neurobiol 2018; 55:9156-9168. [PMID: 29651748 DOI: 10.1007/s12035-018-1063-3] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2018] [Accepted: 04/03/2018] [Indexed: 10/17/2022]
Abstract
Benefits from thrombolysis with recombinant tissue plasminogen activator (rt-PA) after ischemic stroke remain limited due to a narrow therapeutic window, low reperfusion rates, and increased risk of hemorrhagic transformations (HT). Experimental data showed that rt-PA enhances the post-ischemic activation of poly(ADP-ribose)polymerase (PARP) which in turn contributes to blood-brain barrier injury. The aim of the present study was to evaluate whether PJ34, a potent PARP inhibitor, improves poor reperfusion induced by delayed rt-PA administration, exerts vasculoprotective effects, and finally increases the therapeutic window of rt-PA. Stroke was induced by thrombin injection (0.75 UI in 1 μl) in the left middle cerebral artery (MCA) of male Swiss mice. Administration of rt-PA (0.9 mg kg-1) or saline was delayed for 4 h after ischemia onset. Saline or PJ34 (3 mg kg-1) was given intraperitoneally twice, just after thrombin injection and 3 h later, or once, 3 h after ischemia onset. Reperfusion was evaluated by laser Doppler, vascular inflammation by immunohistochemistry of vascular cell adhesion molecule-1 (VCAM-1) expression, and vasospasm by morphometric measurement of the MCA. Edema, cortical lesion, and sensorimotor deficit were evaluated. Treatment with PJ34 improved rt-PA-induced reperfusion and promoted vascular protection including reduction in vascular inflammation (decrease in VCAM-1 expression), HT, and MCA vasospasm. Additionally, the combined treatment significantly reduced brain edema, cortical lesion, and sensorimotor deficit. In conclusion, the combination of the PARP inhibitor PJ34 with rt-PA after cerebral ischemia may be of particular interest in order to improve thrombolysis with an extended therapeutic window.
Collapse
Affiliation(s)
- Mohamad El Amki
- EA4475 - "Pharmacologie de la Circulation Cérébrale", Faculté de Pharmacie de Paris, Université Paris Descartes, Université Sorbonne Paris Cité, 4 avenue de l'Observatoire, 75006, Paris, France
| | - Dominique Lerouet
- EA4475 - "Pharmacologie de la Circulation Cérébrale", Faculté de Pharmacie de Paris, Université Paris Descartes, Université Sorbonne Paris Cité, 4 avenue de l'Observatoire, 75006, Paris, France
| | - Marie Garraud
- EA4475 - "Pharmacologie de la Circulation Cérébrale", Faculté de Pharmacie de Paris, Université Paris Descartes, Université Sorbonne Paris Cité, 4 avenue de l'Observatoire, 75006, Paris, France
| | - Fei Teng
- EA4475 - "Pharmacologie de la Circulation Cérébrale", Faculté de Pharmacie de Paris, Université Paris Descartes, Université Sorbonne Paris Cité, 4 avenue de l'Observatoire, 75006, Paris, France
| | - Virginie Beray-Berthat
- EA4475 - "Pharmacologie de la Circulation Cérébrale", Faculté de Pharmacie de Paris, Université Paris Descartes, Université Sorbonne Paris Cité, 4 avenue de l'Observatoire, 75006, Paris, France
| | - Bérard Coqueran
- EA4475 - "Pharmacologie de la Circulation Cérébrale", Faculté de Pharmacie de Paris, Université Paris Descartes, Université Sorbonne Paris Cité, 4 avenue de l'Observatoire, 75006, Paris, France
| | - Benoît Barsacq
- EA4475 - "Pharmacologie de la Circulation Cérébrale", Faculté de Pharmacie de Paris, Université Paris Descartes, Université Sorbonne Paris Cité, 4 avenue de l'Observatoire, 75006, Paris, France
| | - Charlotte Abbou
- EA4475 - "Pharmacologie de la Circulation Cérébrale", Faculté de Pharmacie de Paris, Université Paris Descartes, Université Sorbonne Paris Cité, 4 avenue de l'Observatoire, 75006, Paris, France
| | - Bruno Palmier
- EA4475 - "Pharmacologie de la Circulation Cérébrale", Faculté de Pharmacie de Paris, Université Paris Descartes, Université Sorbonne Paris Cité, 4 avenue de l'Observatoire, 75006, Paris, France
| | - Catherine Marchand-Leroux
- EA4475 - "Pharmacologie de la Circulation Cérébrale", Faculté de Pharmacie de Paris, Université Paris Descartes, Université Sorbonne Paris Cité, 4 avenue de l'Observatoire, 75006, Paris, France
| | - Isabelle Margaill
- EA4475 - "Pharmacologie de la Circulation Cérébrale", Faculté de Pharmacie de Paris, Université Paris Descartes, Université Sorbonne Paris Cité, 4 avenue de l'Observatoire, 75006, Paris, France.
| |
Collapse
|
3
|
Rani N, Bharti S, Tomar A, Dinda AK, Arya DS, Bhatia J. Inhibition of PARP activation by enalapril is crucial for its renoprotective effect in cisplatin-induced nephrotoxicity in rats. Free Radic Res 2016; 50:1226-1236. [PMID: 27571604 DOI: 10.1080/10715762.2016.1228923] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Oxidative stress-induced PARP activation has been recognized to be a main factor in the pathogenesis of cisplatin-induced nephrotoxicity. Accumulating literature has revealed that ACE inhibitors may exert beneficial effect in several disease models via preventing PARP activation. Based on this hypothesis, we have evaluated the renoprotective effect of enalapril, an ACE inhibitor, and its underlying mechanism(s) in cisplatin-induced renal injury in rats. Male Albino Wistar rats were orally administered normal saline or enalapril (10, 20 and 40 mg/kg) for 10 days. Nephrotoxicity was induced by a single dose of cisplatin (8 mg/kg; i.p.) on the 7th day. The animals were thereafter sacrificed on the 11th day and both the kidneys were excised and processed for biochemical, histopathological, molecular, and immunohistochemical studies. Enalapril (40 mg/kg) significantly prevented cisplatin-induced renal dysfunction. In comparison to cisplatin-treated group, the elevation of BUN and creatinine levels was significantly less in this group. This improvement in kidney injury markers was well substantiated with reduced PARP expression along with phosphorylation of MAPKs including JNK/ERK/p38. Enalapril, in a dose-dependent fashion, attenuated cisplatin-induced oxidative stress as evidenced by augmented GSH, SOD and catalase activities, reduced TBARS and oxidative DNA damage (8-OHDG), and Nox-4 protein expression. Moreover, enalapril dose dependently inhibited cisplatin-induced inflammation (NF-κB/IKK-β/IL-6/Cox-2/TNF-α expressions), apoptosis (increased Bcl-2 and reduced p53, cytochrome c, Bax and caspase-3 expressions, and TUNEL/DAPI positivity) and preserved the structural integrity of the kidney. Thus, enalapril attenuated cisplatin-induced renal injury via inhibiting PARP activation and subsequent MAPKs/TNF-α/NF-κB mediated inflammatory and apoptotic response.
Collapse
Affiliation(s)
- Neha Rani
- a Department of Pharmacology , All India Institute of Medical Sciences , New Delhi , India
| | - Saurabh Bharti
- a Department of Pharmacology , All India Institute of Medical Sciences , New Delhi , India
| | - Ameesha Tomar
- a Department of Pharmacology , All India Institute of Medical Sciences , New Delhi , India
| | - Amit Kumar Dinda
- b Department of Pathology , All India Institute of Medical Sciences , New Delhi , India
| | - D S Arya
- a Department of Pharmacology , All India Institute of Medical Sciences , New Delhi , India
| | - Jagriti Bhatia
- a Department of Pharmacology , All India Institute of Medical Sciences , New Delhi , India
| |
Collapse
|